18.191.223.154
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Home Dr. Ted Maddess highlights the novel, FDA-cleared objectiveField Analyzer

Conference Roundup

Dr. Ted Maddess highlights the novel, FDA-cleared objectiveField Analyzer

Watch Now
By rd360stg
Are geographic atrophy algorithms taking these patients into account?
By rd360stg
AR-15512 shows promise in treating dry eye disease in Phase 3 studies
By rd360stg
Office-based surgical interventions: clinician and patient feedback
By rd360stg
Using TECNIS Odyssey™️ IOL in practice: patient selection and outcomes
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa
By rd360stg
Gene therapy FT-001 shows promise in treating RPE65-related retinal disease
By rd360stg
Six months post-launch of LACRIFILL®️ Canalicular Gel for dry eye disease: what do we know?
By rd360stg
How have treatment options for geographic atrophy made an impact on the field?
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Study links maternal diabetes to severe retinopathy of prematurity risk
By rd360stg
EVO ICL measurement and sizing: what to know
By rd360stg
Study finds that inherited retinal disease impacts overall survival
By rd360stg
PHOTON trial assesses aflibercept 8 mg for diabetic macular edema
-Advertisement-
-Advertisement-
Videos
All
Dr. Ted Maddess highlights the novel, FDA-cleared objectiveField Analyzer
19 Nov, 2024

Dr. Ted Maddess discusses the FDA-cleared ObjectiveFIELD Analyzer, a device...

Are geographic atrophy algorithms taking these patients into account?
15 Nov, 2024
Office-based surgical interventions: clinician and patient feedback
08 Nov, 2024
-Advertisement-
-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-